Cytosorbents (CTSO) Capital Expenditures (2011 - 2026)
Cytosorbents (CTSO) posted Capital Expenditures of $11000.0 for Q1 2026, down 89.81% on a QoQ basis from $108000.0 in Q4 2025, and up 450.0% year-over-year from $2000.0 in Q1 2025.
Cytosorbents (CTSO) Capital Expenditures (2011 - 2026) Analysis & Trends
Cytosorbents' Capital Expenditures history runs 16 years deep, the most recent figure standing at $11000.0 for Q1 2026.
- Quarterly Capital Expenditures rose 450.0% year-over-year to $11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173000.0 (up 591.6% YoY) and the FY2025 annual result came in at $164000.0, up 1950.0% from the prior year.
- Capital Expenditures was $11000.0 for Q1 2026 at Cytosorbents, down from $108000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $5.6 million in Q3 2022 and bottomed at -$5.5 million in Q4 2022.
- A 5-year average of $77220.0 and a median of $27404.5 in 2024 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 563.68% in 2022, while the deepest fall reached 251.43% in 2022.
- Cytosorbents' Capital Expenditures stood at -$5.5 million in 2022, then jumped by 109.76% to $538115.0 in 2023, then tumbled by 138.47% to -$207000.0 in 2024, then soared by 152.17% to $108000.0 in 2025, then plunged by 89.81% to $11000.0 in 2026.
- Business Quant data shows CTSO's Capital Expenditures at $11000.0 in Q1 2026, $108000.0 in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 399.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 166.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 488.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 177.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 64.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 76.60 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -85.46 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 178.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 17,809.00 |
| Jun 30, 2024 | 17,809.00 |
| Mar 31, 2024 | 45,191.00 |
| Mar 31, 2024 | 45,191.00 |
| Dec 31, 2023 | 538,115.00 |
| Dec 31, 2023 | 538,115.00 |